China Pharma Holdings (CPHI) Cash & Equivalents (2010 - 2026)

China Pharma Holdings (CPHI) has reported Cash & Equivalents for 17 consecutive years, with $304874.0 the latest figure, recorded in Q2 2026.

• For the quarter ending Q2 2026, Cash & Equivalents fell 51.22% year-over-year to $304874.0; the trailing twelve-month figure through Jun 2026 stood at $304874.0 (down 51.22% YoY), and the FY2025 full-year result was $345112.0, down 44.95% from the prior year.
• Cash & Equivalents improved to $304874.0 in Q2 2026 per CPHI's latest filing, from $170000.0 in the prior quarter.
• Across five years, Cash & Equivalents topped out at $3.7 million in Q1 2022 and bottomed at $170000.0 in Q1 2026.
• Historically, Cash & Equivalents has averaged $1.1 million across 5 years, with a median of $789109.0 in 2024.
• The sharpest annual moves came in 2022 and 2023: Cash & Equivalents surged 594.97% in 2022, then tumbled 68.59% in 2023.
• Over 5 years, Cash & Equivalents stood at $2.0 million in 2022, then decreased by 29.86% to $1.4 million in 2023, then plunged by 55.97% to $626879.0 in 2024, then plunged by 44.95% to $345112.0 in 2025, then dropped by 11.66% to $304874.0 in 2026.
• According to Business Quant data, Cash & Equivalents over the past three periods registered $304874.0, $170000.0, and $345112.0 for Q2 2026, Q1 2026, and Q4 2025 respectively.